16 fixed-dose combination medicines banned as Centre flags safety concerns

The Centre has taken a significant step in ensuring public health safety by prohibiting the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) drugs. This decision comes after an expert review that found these drugs to be either irrational or lacking in proven therapeutic benefit, thereby posing a potential risk to consumers. The continued use of these drugs was not considered beneficial in relation to the potential risk they posed. The Centre's move is aimed at protecting the health and well-being of the general public by preventing the use of potentially harmful drugs. The expert review that led to this decision was conducted to assess the safety and efficacy of these FDC drugs. The review found that these drugs lacked therapeutic justification, which led to the Centre's decision to ban them. The ban on these 16 FDC drugs is expected to have a positive impact on public health, as it will prevent the use of drugs that have no proven therapeutic benefit. The Centre's decision is a testament to its commitment to ensuring the safety and well-being of the public. The ban will also help to promote the use of safe and effective drugs, which will contribute to better health outcomes for the public. Furthermore, the Centre's move is likely to have a positive impact on the pharmaceutical industry, as it will encourage manufacturers to develop and market safe and effective drugs. The decision to ban these FDC drugs is a significant step towards improving public health safety and promoting the use of safe and effective drugs.